In the fall of 2024, several pharmaceutical companies reacted to HRSA’s decision to prevent them from implementing a rebate model for their respective 340B Programs by filing lawsuits against HHS and HRSA claiming that the Department and its subagency violated their rights under the Administrative Procedure Act and took actions that conflicted with the language of section 42 U.S.C. § 256b(a)(1) of the 340B statute. HHS and HRSA reacted by filing a Cross Motion for Summary Judgment countering…
By: Baker Donelson
By: Baker Donelson
